2-(4-chlorobenzyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: 2-(4-chlorobenzyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol
• 英文别名: 2-[(4-chlorophenyl)methyl]-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol
• 化学式: C₂₀H₂₁ClF₄O₂
• 分子量: 404.832
• InChiKey: AGGMHZBJHNUETP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对氟苯甲醚 在 sodium periodate 、 lithium aluminium tetrahydride 、 三氯化铝 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 2-(4-chlorobenzyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol
  参考文献：
  名称：

  Identification of dissociated non-steroidal glucocorticoid receptor agonists

  摘要：

  A new series of ligands for the glucocorticoid receptor (GR) is described. SAR development was guided by docking 3 into the GR active site and optimizing an trnsubstituted phenyl ring for key interactions found in the steroid A-ring binding pocket. To identify compounds with an improved side effect profile over marketed steroids the functional activity of compounds was evaluated in cell based assays for transactivation (aromatase) and transrepression (IL-6). Through this effort, 36 has been identified as a partial agonist with a dissociated profile in these cell based assays. (c) 2007 Elsevier Ltd. All riehts reserved.

  DOI：

  10.1016/j.bmcl.2007.07.031

文献信息

• [EN] GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] MIMETIQUES DU GLUCOCORTICOIDE, PROCEDES DE FABRICATION DE CES MIMETIQUES, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2003082787A1

  公开（公告）日：2003-10-09

  Compounds of Formula (IA) and Formula (IB) wherein R1, R2, R3, R4, R5, and R6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate,or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  式（IA）和式（IB）的化合物，其中R1、R2、R3、R4、R5和R6如本说明所定义的适用于式（IA）或式（IB），或其互变异构体、前药、溶剂化合物或盐；含有这些化合物的药物组合物，以及利用这些化合物调节糖皮质激素受体功能的方法、治疗由糖皮质激素受体功能介导的疾病状态或病情特征或患者体内的炎症、过敏或增殖过程的方法。
• Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040029932A1

  公开（公告）日：2004-02-12

  Compounds of Formula (IA) and Formula (IB) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined herein for Formula (IA) or Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  化合物的公式（IA）和公式（IB）1，其中R1、R2、R3、R4、R5和R6如公式（IA）或公式（IB）所定义，或其互变异构体、前药、溶剂化物或盐；包含这些化合物的药物组合物；以及使用这些化合物调节糖皮质激素受体功能、治疗由糖皮质激素受体功能介导或以炎症、过敏或增生过程为特征的疾病状态或情况的方法。
• GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
  申请人：BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

  公开号：EP1490317A1

  公开（公告）日：2004-12-29
• US7268152B2
  申请人：——

  公开号：US7268152B2

  公开（公告）日：2007-09-11
• Identification of dissociated non-steroidal glucocorticoid receptor agonists
  作者：Daniel Kuzmich、Tom Kirrane、John Proudfoot、Younes Bekkali、Renee Zindell、Laura Beck、Richard Nelson、Cheng-Kon Shih、Alison J. Kukulka、Zofia Paw、Patty Reilly、Rodney Deleon、Mario Cardozo、Gerald Nabozny、David Thomson

  DOI：10.1016/j.bmcl.2007.07.031

  日期：2007.9

  A new series of ligands for the glucocorticoid receptor (GR) is described. SAR development was guided by docking 3 into the GR active site and optimizing an trnsubstituted phenyl ring for key interactions found in the steroid A-ring binding pocket. To identify compounds with an improved side effect profile over marketed steroids the functional activity of compounds was evaluated in cell based assays for transactivation (aromatase) and transrepression (IL-6). Through this effort, 36 has been identified as a partial agonist with a dissociated profile in these cell based assays. (c) 2007 Elsevier Ltd. All riehts reserved.